Citius Pharmaceuticals emphasizing on adjunctive cancer care and critical care drug products affirmed the enrollment of first patient into the Mino-Lok Phase 3 Clinical Trial for catheter related bacteremias at the Henry Ford Health System in Detroit, Michigan.
The Mino-Lok trial is a Phase 3, Multi-Center, Randomized, Open-Label, Assessor-Blind Study to Evaluate the Efficacy and Safety of Mino-Lok Therapy in Combination with Systemic Antibiotics in the Treatment of Catheter-Related Bloodstream Infections.
Patients with CRBSI may be at risk for serious complications, including septic thrombosis, endocarditis, and disseminated infection. Many of these patients need to have their central venous catheters (“CVCs”) removed and subsequently replaced, causing added costs, morbidities and discomfort. Removal and reinsertion of a new CVC may be difficult or even impossible due to the unavailability of other accessible vascular sites.
Mr. Myron Holubiak, President and CEO of Citius said “We believe we are at the forefront of providing much needed evidence that antibiotic lock therapy is an attractive alternative to removing and replacing infected central lines. This will be the largest and most definitive study of its kind conducted to date.”